Pobitra Borah, Pran Kishore Deb*, Satyendra Deka, Katharigatta N. Venugopala, Vinayak Singh, Raghu Prasad Mailavaram, Kiran Kalia and Rakesh Kumar Tekade* Pages 284 - 307 ( 24 )
The COVID-19 pandemic continues to wreak havoc worldwide due to the lack of risk assessment, rapid spreading ability, and propensity to precipitate severe disease in comorbid conditions. In an attempt to fulfill the demand for prophylactic and treatment measures to intercept the ongoing outbreak, the drug development process is facing several obstacles and renaissance in clinical trials, including vaccines, antivirals, immunomodulators, plasma therapy, and traditional medicines. This review outlines the overview of SARS-CoV-2 infection, significant recent findings, and ongoing clinical trials concerning current and future therapeutic interventions for the management of advancing pandemic of the century.
COVID-19, SARS-CoV-2, Cytokine Storm, Remdesivir, TCM, Convalescent Plasma, Vaccines.
Pratiksha Institute of Pharmaceutical Sciences, Chandrapur Road, Panikhaiti, Guwahati-781026, Assam, Department of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, PO Box 1, Amman 19392, Pratiksha Institute of Pharmaceutical Sciences, Chandrapur Road, Panikhaiti, Guwahati-781026, Assam, Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Drug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch, 7701, Department of Pharmaceutical Chemistry, Shri Vishnu College of Pharmacy, Vishnupur, Bhimavaram – 534 202, West Godavari Dist., Andhra Pradesh, National Institute of Pharmaceutical Education and Research– Ahmedabad (NIPER-A), Opposite Air Force Station Palaj, Gandhinagar-382355, Gujarat, National Institute of Pharmaceutical Education and Research– Ahmedabad (NIPER-A), Opposite Air Force Station Palaj, Gandhinagar-382355, Gujarat